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ABSTRACT OF DISSERTATION

IMPAIRED GLUCOSE METABOLISM IN THE ABSENCE OF SKELETAL
MUSCLE BRAIN AND MUSCLE ARNT-LIKE-PROTEIN 1 (BMAL1)
Metabolism is a critical physiological function that works to generate energy for
cells, store substrates and maintain homoeostasis. Alterations in normal metabolism can
have a severe effect on physiology, leading to metabolic disease. Skeletal muscle is a key
metabolic tissue, taking up ~80% of postprandial glucose. Therefore it contributes
considerably to glucose metabolism: glucose uptake, oxidation and homeostasis. To
address the role of the skeletal muscle clock in insulin sensitivity and glucose tolerance,
our lab generated an inducible skeletal muscle specific Bmal1-/- mouse (iMSBmal1-/-). 5
weeks post-recombination we observed impairment in both insulin- and AICARstimulated skeletal muscle glucose uptake. RT-PCR and western blot analysis
demonstrated a significant decrease in mRNA expression and protein content of the
skeletal muscle glucose transporter, Glut4. Glucose uptake may be affected by glucose
utilization so we examined aspects of glycolysis in the skeletal muscle. Both mRNA
expression and activity of rate limiting enzymes hexokinase 2 (Hk2) and
phosphofructokinase 1 (Pfk1) were significantly reduced. Additionally, metabolomics
illustrated a reduction in metabolites of the glycolytic pathway further supporting a
decrease in glycolytic flux. These changes in skeletal muscle glucose metabolism led to
altered overall body metabolic health. iMSBmal1-/- mice presented with glucose
intolerance and non-fasting hyperglycemia. Furthermore, changes in body composition
were seen from 5-12 weeks post-recombination. These data propose a critical role for
skeletal muscle Bmal1 in both skeletal muscle glucose metabolism and overall body
metabolic health. The presented findings also illuminate skeletal muscle Bmal1 and
circadian rhythms as potential targets for metabolic disease.

KEYWORDS: Circadian rhythms, glucose metabolism, skeletal muscle, glucose uptake,
glycolysis.
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CHAPTER 1: Introduction and Background

1.1 General Introduction
The importance of skeletal muscle to health is often underestimated, yet skeletal
muscle is the most abundant tissue in the human body, comprising approximately
45% of total body mass (Goodpaster et al., 2000; Hoppeler and Fluck, 2002).
Skeletal muscle tissue is an intricate network of over 600 individual muscles that
have different fiber type compositions, metabolic capacities and mechanical functions
(Poole, 1986). As a whole, skeletal muscle tissue is critical for systemic health and
quality of life. It is well understood that skeletal muscle functions to produce force
and enable locomotion, but skeletal muscle is involved in a number of integral
processes that are frequently forgotten. Skeletal muscle serves as a principal
reservoir for amino acids in the absence of nutrient intake, thereby allowing the
maintenance of protein synthesis in other tissues. This supply of amino acids also
serves as a pool of precursors for hepatic gluconeogenesis, which is significant in
sustaining blood glucose levels in the fasting state (Ripperger et al., 1995). Not only
does skeletal muscle serve as a reserve of amino acids, but it also acts as a depot for
glucose in the postprandial state. As much as 80% of postprandial glucose is taken up
by skeletal muscle (Defronzo et al., 1981; Ferrannini et al., 1988). Consequently,
skeletal muscle is vital for systemic level glucose homeostasis.
Changes in muscle composition and function are strongly correlated with disease
development. One the most common conditions in the United States is metabolic
disease. This category of disease includes but is not limited to diabetes, obesity,
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insulin resistance and impaired glucose tolerance. In the U.S., as much as 22% of the
population has diabetes mellitus, 17% exhibits impaired glucose tolerance, 32% are
obese and approximately 35% meet criteria for metabolic syndrome (Golden et al.,
2009). Metabolic disorders are a major health issue and have an unmistakable
association with impaired muscle metabolism (Nuutila et al., 1993; Petersen et al.,
2007; DeFronzo and Tripathy, 2009; Mitrou et al., 2011; Preisler et al., 2015). Two
critical metabolic functions of skeletal muscle are glucose uptake and glucose
oxidation. These functions both help maintain glucose homeostasis and provide
energy for skeletal muscle cells. It is clear that changes in skeletal muscle metabolic
function, which often manifests as altered glucose uptake and substrate oxidation,
affect human health. Recently however, a new skeletal muscle property has been
implicated in the regulation of skeletal muscle metabolism and the conservation of
metabolic health. Skeletal muscle, like virtually every cell in the body has circadian
rhythms. Recent studies have begun to demonstrate that disruptions in circadian
rhythms may play a crucial role skeletal muscle metabolic dysfunction and metabolic
disease development (Yoo et al., 2004; Andrews et al., 2010; Dyar et al., 2014).
Although it is accepted that skeletal muscle cells have their own circadian
rhythms, the concept of skeletal muscle circadian rhythms is still quite new. Even
more recent is the idea that skeletal muscle circadian rhythms contribute to skeletal
muscle metabolism, but very little is yet known. This dissertation aims to further
investigate the role of skeletal muscle circadian rhythms in one of the more critical
metabolic functions of skeletal muscle, glucose metabolism. In addition, it explores
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the idea that exclusive disruption of skeletal muscle rhythms, and therefore skeletal
muscle metabolism, will have an effect on overall metabolic health.

1.2 Circadian rhythms, skeletal muscle and metabolism
1.2.1 Circadian rhythms in skeletal muscle
As previously stated, skeletal muscle, similar to almost every cell of the body, has
circadian rhythms. These rhythms are generated by a transcriptional-translational
feedback loop known as the molecular clock and this mechanism has been reviewed in
more complete detail elsewhere (Shearman et al., 2000; Buhr and Takahashi, 2013;
Robinson and Reddy, 2014). At a basic level, Clock, Bmal1, Cry1/2 and Per1/2 are all
core molecular clock components (Kume et al., 1999; Shearman et al., 2000). Bmal1 and
Clock make up the positive limb of the molecular clock. They are bHLH transcription
factors, which heterodimerize in the nucleus and transactivate Per and Cry family genes
by binding E-box elements in their regulatory regions. PER and CRY then accumulate,
multimerize, and translocate to the nucleus where they inhibit BMAL1:CLOCK activity,
thereby repressing their own expression. The accumulation of PER and CRY protein is
also tightly controlled through phosphorylation and degradation via E3 ubiquitin ligases
and the proteasome system so that inhibition of BMAL1:CLOCK activity is lifted
(Gallego and Virshup, 2007; Yoo et al., 2013) (Figure 1.1). Proper timing of the
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Figure 1.1. Diagram of the skeletal muscle molecular clock. CLOCK and BMAL1
heterodimerize and bind to e-box sequences in the promoter of the period (Per) and
Cryptochrome (Cry) genes, promoting Per and Cry transcription. After PER and CRY are
translated in the cytoplasm, they heterodimerize and are translocated to the nucleus where
they inhibit the activity of BMAL1:CLOCK, thereby inhibiting their own transcription.
In this general manner an oscillation of ~24 hours is generated.

molecular clock mechanism requires transcription, translation and important rate
modifying post-translational steps, thus, presenting many sites through which information
from environmental cues and physiological function can support or modify the clock.
Aside from a timekeeping role, the clock modulates the transcription of a large
number of genes within the cell (clock-controlled genes [CCGs]); some of these are
regulated directly by the binding of the core clock transcription factors Bmal1 and/or
Clock to their promoters. To date, the identities of the direct clock controlled genes in a
specific tissue, like skeletal muscle, have not been defined, but circadian transcriptome
results suggest that they often encode transcription factors (e.g. MyoD1, Pgc1α) or
proteins that control rate-limiting steps in cell physiology (e.g. Pdk4, Dbp) (Figure 1.2).
Tissue specific detailed reviews of the molecular clock mechanism and CCG’s within
individual tissues are available in several recent reviews by other groups
4

Figure 1.2. Simplified cartoon highlighting the function of the molecular clock as a timekeeping mechanism as well as modulating expression of genes important for skeletal
muscle function (in particular metabolism).

(Panda et al., 2002; Storch et al., 2002; Kornmann et al., 2007; Nakahata et al., 2008;
Lee et al., 2013; Shostak et al., 2013). The most direct evidence for the contribution of
BMAL1:CLOCK regulation of gene expression outside of the timekeeping function
comes from chromatin immunoprecipitation studies followed by DNA sequencing. These
studies, performed in liver, determined that the BMAL1:CLOCK transcription factors
bind to over 2000 sites across the chromatin with up to 85% of the sites being associated
with actively expressed genes. Gene ontology analysis showed that the BMAL1:CLOCK
targeted expressed genes are highly enriched for metabolic, cancer and insulin signaling
pathways in liver (Rey et al., 2011; Koike et al., 2012). Chromatin immunoprecipitation
studies have not yet been performed in skeletal muscle, but the results from liver
highlight the breadth of transcriptional regulation by the molecular clock factors BMAL1
and CLOCK.
Although more thorough investigations of molecular clock targets are needed in
skeletal muscle, there have been studies identifying circadian-expressed genes using
expression profiling. The first paper to define circadian gene expression in skeletal
muscle was published in 2007 and identified 215 circadian genes (McCarthy et al., 2007).
5

However, increased sampling frequency, with tissues collected every two hours for 48
hours, and continued development of analysis tools for circadian gene expression studies
has expanded this list to greater than 2300 genes (Pizarro et al., 2013). A large portion of
these genes are involved in metabolism, transcription and signaling in muscle (McCarthy
et al., 2007). The function of the molecular clock in skeletal muscle is only starting to be
uncovered. Our lab has quite recently conducted a study analyzing publicly available,
high-resolution microarray data in the skeletal muscle of mice. A total of 1,628 mRNAs
were classified as circadian mRNAs; genes that showed an approximate 24 hour
rhythmicity. Gene ontology was used to look for processes that were enriched in skeletal
muscle circadian mRNAs. Of the identified 1,628 skeletal muscle circadian genes, 62%
were enriched for metabolic processes. This provides strong evidence for a function of
the skeletal muscle molecular clock in regulating skeletal muscle metabolism. Of
particular relevance to this dissertation are the results obtained from investigating
changes in gene expression when the skeletal muscle molecular clock is impaired. To
look at this, we examined the skeletal muscle of mice that had a skeletal muscle specific
induced knock out of the core molecular clock gene, Bmal1 (iMSBmal1-/- mice). The
skeletal muscle process most affected by loss of skeletal muscle Bmal1 was carbohydrate
metabolism (Hodge et al., 2015b). This data suggests that one of the major roles of
skeletal muscle Bmal1 and circadian rhythms is to regulate skeletal muscle carbohydrate
metabolism.

1.2.2 Entrainment of skeletal muscle circadian rhythms

6

Circadian rhythms are oscillations over a period of approximately 24 hours, and in
skeletal muscle these rhythms include oscillations in transcription, myogenic capacity
and notably metabolism (Andrews et al., 2010; Chatterjee et al., 2011; Zhang et al.,
2012). This oscillation of physiological processes is believed to be beneficial as it allows
an organism to anticipate changes in environmental cues. These rhythms run in the
absence of any external environmental cues, but a fundamental property of circadian
rhythms is the ability to be entrained. The molecular clock has a phase, defined as the
time relative to a specific point of the circadian cycle. For example, phase of the
molecular clock may be determined by the time of peak Bmal1 expression. Entrainment
occurs when the phase of the molecular clock is reset or modulated to be aligned with the
timing of an environmental cue, such as light (Roenneberg et al., 2003). The skeletal
muscle molecular clock can be entrained by cues such a light, time of feeding and
activity. In the case of light, the skeletal muscle clock is entrained in an indirect manner
through the central clock in the suprachiasmatic nucleus (SCN). Light is transmitted via
the retinohypothalamic tract from the retina to the SCN. Light evokes signaling in the
SCN, through elements such as cyclic-AMP, that then modulate the molecular clock to
affect the peak/phase of molecular clock oscillations (Gooley et al., 2001; Panda et al.,
2002b; Lee et al., 2010; An et al., 2011). The SCN molecular clock communicates with
other tissues, such as the skeletal muscle, using neurohumoral and temperature signals
(Balsalobre et al., 2000; Brown et al., 2002; Abraham et al., 2010; Saini et al., 2012). It
is in this indirect manner that the skeletal muscle clock is modulated by light cues.
Time of feeding also serves as an entrainment cue. Studies of time restricted
feeding in mice have demonstrated a phase shift in core molecular clock genes in liver
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and adipose tissue (Hara et al., 2001; Stokkan et al., 2001; Zvonic et al., 2006). In liver,
this was shown to be independent of SCN input, since time restricted feeding prevented
the shift of the clock genes when the mice were exposed to a 7-hour light:dark cycle
advance (Hara et al., 2001). Although research on time of feeding and skeletal muscle is
limited, time of feeding has been shown to entrain skeletal muscle circadian rhythms. A
study from our lab demonstrated this using PER2:LUC mice. These mice were developed
by Yoo et. al. and have luciferase cDNA knocked into the Per2 coding region to generate
a chimeric protein. Tissues from these mice may be explanted and placed in culture with
luciferin to observe real time light emission as an indicator of PER2, and thus molecular
clock oscillations (Yoo et al., 2004). To evaluate the effect of time of feeding on skeletal
muscle rhythms, our lab limited access to food for only 4 hours/day for two weeks. The
restricted feeding resulted in a shift in gene expression (PER2:LUC bioluminescence) in
the skeletal muscle of the mice. In addition to studying the effect of time restricted
feeding, our lab also demonstrated the ability of scheduled activity to entrain the skeletal
muscle molecular clock (Wolff and Esser, 2012). Schedule bouts of either voluntary or
involuntary endurance exercise resulted in a significant shift in clock gene expression
(PER2:LUC bioluminescence) in 3 different muscle types as well as the lung. The shift in
gene expression was observed in these tissues but not in the SCN, supporting a role for
exercise as a non-SCN associated entrainment cue for skeletal muscle. Notably, the phase
of the each of the three muscles, soleus, extensor digitorum longus (EDL) and flexor
digitorum brevis (FDB), pre-exercise was distinct, highlighting the complexity of skeletal
muscle and skeletal muscle circadian rhythms. This may be due to the differences in
composition and function of the three muscles. The soleus is a postural muscle that is
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comprised of mostly type I slow, oxidative fibers, whereas the EDL and FDB are
intermittently recruited muscles (for either extension or flexion of the toes) and
comprised of more type II fast oxidative-glycolytic and glycolytic fibers. Despite
differences in the pre-exercise phase of the muscles, scheduled activity shifted the phases
to about the same magnitude, 2-3 hours (Wolff and Esser, 2012). In addition, studies with
the ClockΔ19 mice have demonstrated decreases in protein levels of proliferator-activated
receptor-γ coactivator-1 α (PGC1α) and mitochondrial transcription factor A with a
concomitant decrease in mitochondrial content in skeletal muscle. Access to a running
wheel under conditions of 12-hr:12-hr dark/light cycle and ad libitum access to food
resulted in daily exercise (during the dark/active phase) in the clock mutant mice which
partially rescued the metabolic phenotype of the skeletal muscle (Pastore and Hood,
2013). This illustrates the potential impact physical activity may have as an entrainment
cue for skeletal muscle and also suggests that entrainment cues for skeletal muscle may
be useful as therapies in conditions of circadian disruption.
The concept entrainment is important for this dissertation solely due to the fact
that the mice used have impaired skeletal muscle circadian rhythms and therefore cannot
be entrained to environmental cues. As a result, one can expect that skeletal muscle will
not be able to anticipate and respond to the environment, such as metabolic changes
(more specifically changes in glucose), and this may have detrimental effects on skeletal
muscle metabolism, glucose homeostasis and metabolic health.

1.2.3 Synchrony of circadian rhythms in skeletal muscle and other metabolic tissues
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Circadian research also demonstrates that synchrony of circadian rhythms in
different tissues is important for normal physiology. This should be noted because
synchrony of rhythms between metabolic tissues (skeletal muscle, liver, adipose) is
necessary for normal metabolic function and health. A study by Yoo et. al. using the
PER2:LUC mice demonstrated that peripheral (non-SCN) tissues had oscillators and that
these oscillators had very distinct phases. Furthermore, they illustrated the importance of
coordination of the tissue clocks by lesioning the SCN. In the presence of a lesioned
SCN, the mice behave arrhythmically and the clocks in other tissues no longer express
their normal phase relationships (Yoo et al., 2004).
As mentioned earlier, expression of genes involved in metabolism have been
shown to oscillate in skeletal muscle. In fact, in the study by McCarthy et. al., one of the
largest groups of oscillatory genes in skeletal muscle consisted of genes involved in
substrate metabolism (McCarthy et al., 2007). Skeletal muscle and liver are considered
key metabolic tissues and as such, it follows that coordination between these tissues
would be critical for normal metabolic function at the systems level. A complete
investigation of the coordination of the metabolic functions of these tissues in regards to
circadian rhythms has not been done. However, data on the expression of circadian genes
in skeletal muscle and liver has been collected and is available on the database CircaDB
(Pizarro et al., 2013). Muscle and liver serve as tissues that participate in the regulation of
blood glucose. From CircaDB one can see that genes involved in insulin signaling (Irs1,
Irs2, Akt2, and Tbc1d1) and genes important for hepatic glucose production (Pck1, G6pc,
Pep and Pyg) are circadian in both of these tissues and the phases are coordinated in a
manner to facilitate blood glucose regulation (Table 1). Although protein and activity
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Table 1. Circadian genes involved in carbohydrate homeostasis. Approximate time of
peak expression in skeletal muscle and liver based on CircaDB (Pizarro et al., 2013).
Dark gray represents the dark phase and light gray represents the light phase.
Unhighlighted numbers represents borderline light/dark times.

data is essential to confirm the gene data, it is apparent in Table 1 that during the light
phase (or fasting phase for mice) genes involved in insulin signaling (Irs1, Tbc1d1, Akt
and Insr) have reduced expression in both skeletal muscle and liver. During this time,
genes involved in hepatic glucose production (Pck1, G6pc, Pep and Pyg) have increased
expression. Furthermore, it has been shown in rodents that hepatic glucose production
peaks during the fasting phase at which time insulin sensitivity is low (la Fleur et al.,
2001; Matsumoto et al., 2007; Zhang et al., 2010). In contrast to the fasting phase, it is
necessary for greater insulin sensitivity in the metabolic tissues during the feeding phase
in order to take up and store post-prandial glucose (Oakes et al., 1997; Radziuk and Pye,
2001). Furthermore, the feeding phase is also often the active phase during which skeletal
muscle requires more substrate. Therefore, during the feeding/active phase insulin
sensitivity in liver and skeletal muscle needs to be higher (Figure 2). In this regard,
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Figure 1.3. Cartoon depicting time-of-day coordination between skeletal muscle and
liver metabolism for the regulation of systems glucose homeostasis. The dark phase/fed
phase for mice is characterized by higher insulin sensitivity in skeletal muscle/liver and
decreased hepatic glucose production. The light phase/fasting phase for mice is
characterized by reduced insulin sensitivity in skeletal muscle/liver and increased hepatic
glucose production.

synchrony between the skeletal muscle and other tissues is critical to normal
physiological function.
The mice used in this dissertation have non-functional BMAL1 and have
therefore lost skeletal muscle circadian rhythms. In the absence of skeletal muscle
circadian rhythms, the skeletal muscle will lose the ability to synchronize rhythms with
other metabolic tissues and this may contribute to impaired skeletal muscle metabolism
and development of metabolic disorders. This will also be important later as some
changes in the liver are seen despite the fact that Bmal1 was only knocked down in
skeletal muscle.
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1.2.4 Skeletal muscle metabolism in circadian mutant models
The role of circadian clocks in regulating physiological processes has been largely
studied through the use of genetic mouse models of clock disruption. These models
include the Per1/Per2 deficient mice, Cry1/Cry2 double knockouts, Clock-/-, ClockΔ19 and
Bmal1-/- mice. The first mouse model of clock disruption, the ClockΔ19, was identified
through a forward genetics screen and is a mouse model in which exon 19 (an exon
critical for the DNA binding of the Clock gene) is mutated. These mice have a free
running period of 28 hours, becoming behaviorally arrhythmic after 1-2 weeks in
constant darkness (Vitaterna et al., 1994). ClockΔ19 mice are moderately more susceptible
to cancer and display a marked metabolic phenotype involving obesity, dyslipidemia,
hepatic steatosis and hyperglycemia (Rudic et al., 2004; Turek et al., 2005; Lee et al.,
2010). Interestingly, the Clock-/- mice (mice deficient of the Clock gene due to targeted
gene knock down) do not exhibit the same phenotype as the ClockΔ19 mice. Clock-/display a slightly shorter period length with preserved behavioral rhythms. They have
reduced lifespan, age-related cataract development and increased risk for dermatitis
(Debruyne et al., 2006; DeBruyne et al., 2007; Dubrovsky et al., 2010). Differences
between ClockΔ19 and Clock-/- mouse models likely arise from the fact that the ClockΔ19
mice have a dominant negative mutation in Clock whereas Clock-/- are deficient of Clock
altogether and may have compensation from NPAS2. Models involving genes of the
negative limb of the molecular clock, Period and Cryptochrome, appear to have less
severe consequences in comparison to the Clock-/- and ClockΔ19 mice. Period and
Cryptochrome knockout mice do not display altered lifespan and the serious
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physiological phenotype observed in ClockΔ19 and Bmal1-/- mice. However, absence of
Period does result in greater susceptibility to diet induced obesity (Yang et al., 2009).
Of the studied circadian mouse models, Bmal1-/- mice exhibit the most severe
pathology. These mice display significantly reduced lifespan, behavioral arrhythmicity,
ectopic calcification and sterility (Bunger et al., 2005; Kondratov et al., 2006; Yu and
Weaver, 2011), and as such Bmal1 is the circadian gene that is more commonly targeted
in to study circadian disruption.
Disruption of circadian rhythms is associated with an increased risk for
development of metabolic disruption in both animals and humans (Karlsson et al., 2001;
Rudic et al., 2004; Turek et al., 2005; Kroenke et al., 2007; Morikawa et al., 2007;
Scott et al., 2008; Scheer et al., 2009; Marcheva et al., 2010). Besides the detrimental
consequences of Bmal knockout on lifespan, bone health and arrhythmicity, Bmal1-/mice show severe metabolic changes. These mice exhibit impaired insulin sensitivity,
glucose tolerance and age-associated weight decline (Rudic et al., 2004; Kondratov et
al., 2006; Andrews et al., 2010). As stated earlier, skeletal muscle comprises ∼45% of
the body mass of most mammals and is a critical component of normal metabolic health.
Skeletal muscle is responsible for approximately 80% of postprandial insulin-mediated
glucose disposal (DeFronzo et al., 1981; Ferrannini et al., 1988). In addition, altered
muscle function can contribute to insulin resistance and metabolic syndrome (Kelley et
al., 1999; Petersen et al., 2007). Our previous work in the germline Bmal1-/- mice
demonstrated that Bmal1-/- and ClockΔ19 mice display ~40 percent decrease in skeletal
muscle mitochondrial volume. The mitochondria present in these mutant mice displayed
aberrant morphology and increased respiratory uncoupling. Specifically a significant
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reduction in state III respiration (ADP-stimulated, mmol O2/min/mg protein) in
mitochondria isolated from gastrocnemius (GTN) muscle was observed (Andrews et al.,
2010). There are limited studies on skeletal muscle specific Bmal1 knockout mice and
they demonstrate a significant impact on muscle metabolism as well. As mentioned
previously, our lab showed that the most affected process in skeletal muscle of
iMSBmal1-/- mice is carbohydrate metabolism. In another study by Dyar et.al., muscle
specific loss of Bmal1 resulted in decreased skeletal muscle glucose uptake, reduced
glucose oxidation, and increased PDK4 expression (Dyar et al., 2014). The increase in
PDK4 expression coupled with an observed shift toward more oxidative fibers in the
soleus muscle may indicate greater use of lipids for energy metabolism in the muscle of
skeletal muscle specific Bmal1 KO mice. These data demonstrate the importance the
skeletal muscle molecular clock in the maintenance of systemic metabolic health. More
importantly, they set the foundation of this dissertation by illuminating a role of the
skeletal muscle clock in skeletal muscle glucose metabolism.

1.3 Skeletal muscle glucose metabolism
1.3.1 General background on glucose metabolism
Metabolism is a complex physiological function that includes all the chemical
reactions of the body necessary to maintain life. This involves reactions in digestion,
release of endocrine hormones, transport of substrates into cells, reactions used to
produce cellular energy and much more (Marieb and Hoehn, 2012). Metabolism is
essential for providing cellular energy, but also crucial in helping living organisms
maintain homeostasis (Marieb and Hoehn, 2012; Wilson, 2013). For the purposes of this
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dissertation it is important to understand glucose metabolism and glucose homeostasis.
Glucose, a six-carbon hexamer, is one of the major energy substrates utilized by cells to
produce ATP. Generally, when looking at dietary components, glucose is obtained from
carbohydrates. These carbohydrates are catabolized into one of three simple sugars:
glucose, fructose or galactose. Fructose and galactose can be converted to glucose in
order to be metabolized via the glycolytic pathway. Glucose may also be obtained by
gluconeogenesis or glycogenolysis. Gluconeogenesis is the conversion of fats and amino
acids into glucose. Glycogenolysis is the breakdown of the highly branched storage form
of glucose known as glycogen. Glucose is very strictly regulated in the body; blood
glucose is maintained between 70-110 mg/dL of blood in humans. If glucose drops too
low it can cause a range of symptoms from dizziness to seizures to even death. This can
be attributed to the fact that certain tissue types, specifically neural tissue, relies almost
entirely on glucose for metabolism. Therefore, when blood glucose is low, there is not
enough energy substrate for neural tissue (such as the brain) to meet metabolic demands.
In contrast, if blood glucose is elevated for too long it can lead to detrimental effects such
as inflammatory responses, loss of fluid from cells (crenation as water osmosizes out of
the cell to balance concentrations), build-up of atherosclerotic plaques over time and in
severe cases stroke. As such, it is critical that the metabolism function normally to
maintain glucose homeostasis. There are two well recognized metabolic states: the fed or
postprandial state and the fasted state. In the postprandial state, after ingestion of a meal,
blood glucose goes up and must be disposed of from the blood by metabolic tissues,
generally as a result of insulin action. Insulin is released from the pancreas in response to
elevated glucose and acts on tissues to increase glucose uptake, storage and utilization.
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In the fasted state, blood glucose starts to drop and metabolism must work to bring it
back up, usually through the release of anti-insulin acting hormones: glucagon, growth
hormone, cortisol, epinephrine and norepinephrine (Beitner and Kalant, 1971; Marieb
and Hoehn, 2012).
As previously stated, skeletal muscle is the largest metabolic organ in the nonobese individual and accounts for up to 80% of glucose metabolism in the postprandial
state (DeFronzo et al., 1985; Ferrannini et al., 1985; Eckardt et al., 2014). Two of the
metabolic processes in skeletal muscle that help maintain glucose homeostasis and
provide cellular energy are glucose uptake and glycolysis. These two processes will be
the main focus of this dissertation.

1.3.2 Skeletal muscle glucose uptake
Skeletal muscle glucose uptake is the process by which extracellular glucose is
transported across the plasma membrane and into the skeletal muscle cell via facilitated
diffusion. In skeletal muscle, glucose transport is mainly facilitated by glucose
transporter type 4 (GLUT4) (Eguez et al., 2005). Uptake of glucose can be regulated in
three distinct ways: delivery of glucose to skeletal muscle (circulation), transport of
glucose across the membrane (presence and function of GLUT4), and utilization of
glucose by skeletal muscle cells (glucose oxidation or glycolysis) (Wasserman et al.,
2011; Richter and Hargreaves, 2013). This study concentrates on the latter two. In the
basal state, GLUT4 is primarily located in intracellular stores and glucose transport
across the membrane is minimal. Early studies demonstrate that GLUT4 localizes to a
number of different intracellular compartments and organelles including the Golgi body,
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trans-Golgi network, lysosomes, and late- and recycling-endosomes (Tanner and
Lienhard, 1987; Kandror and Pilch, 1994; Hanpeter and James, 1995; Ralston and
Ploug, 1996). There is some controversy over whether the intracellular pool of GLUT4 is
static or if it is dynamic and constantly recycled between plasma membrane and the
intracellular compartments, but regardless, membrane GLUT4 is kept nominal until
stimulation. Upon stimulation, intracellular signaling occurs that results in translocation
of GLUT4 to the cell membrane. The recognized triggers for GLUT4 translocation are
insulin and contraction (Cushman and Wardzala, 1980; Constable et al., 1988; Douen et
al., 1990; Goodyear et al., 1990; Brozinick et al., 1992; Czech and Buxton, 1993;
Kanai et al., 1993; Cheatham and Kahn, 1995). Insulin and contraction signaling are two
distinct pathways. This is known since contraction stimulated glucose uptake can occur
normally in the presence of insulin resistance. However, they have some signaling
molecules in common and both produce the same ultimate outcome, which is GLUT4
translocation to the membrane and increased glucose uptake (Ploug et al., 1987;
Brozinick et al., 1992; Dolan et al., 1993; Lee et al., 1995; Kramer et al., 2006a;
Kramer et al., 2006b; Taylor et al., 2008).
Insulin signaling initiates following binding of insulin to the insulin receptor (IR)
(Cheatham and Kahn, 1995). The insulin receptor is a heterotetrameric complex
consisting of two alpha subunits and two beta subunits. The alpha subunits bind insulin
and the beta subunits possess tyrosine kinase activity. Insulin binding of the alpha
subunits of the IR provokes trans-phosphorylation of specific tyrosines in the beta
subunits which further increase the tyrosine kinase activity and allows particular
molecules, insulin receptor substrates 1 and 2 (IRS1, IRS2) to dock. IRS1 and IRS2
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contain Src homology (SH2) domains that recognize specific phosphotyrosine residues in
the active IR. Once docked, IRS1 and IRS2 are phosphorylated and thus are able to
interact with the next signaling molecule, phospho-inositol 3-kinase (PI3K) via its p85
regulatory subunit (Saltiel and Pessin, 2003; Watson et al., 2004). This interaction brings
PI3K in proximity to the plasma membrane allowing it to convert phosphotidylinositol
4,5-bisphosphate (PIP2) to phosphotidylinositol 3,4,5-triphosphate (PIP3) (Shepherd,
2005). The presence of PIP3 recruits molecules with pleckstrin homology (PH) domains –
phosphoinositide dependent-kinase 1 (PDK1) and protein kinase B (AKT2) – to the
membrane where PDK1 can phosphorylate and activate AKT2 (Corvera and Czech,
1998; Mora et al., 2004). AKT2 has many potential substrates that have been identified
but only TBC1 domain family member 4 (TBC1D4 or AS160) and TBC1 domain family
member 1 (TB1D1) have been studied in more detail. It is known that TBC1D1 and
TBC1D4 inhibit GLUT4 translocation in the basal/unstimulated state. Translocation of
GLUT4 to the membrane is controlled by Rab proteins, small proteins that are part of the
Ras superfamily of monomeric G proteins. When bound to GTP, Rab proteins are active
and facilitate trafficking of GLUT4 to the membrane. When bound to GDP they are
inactive and GLUT4 translocation is low (Satoh, 2014). TBC1D1 and TBC1D4 have
Rab-GTPase activity that regulates the activity of Rab proteins. Under basal conditions,
TBC1D1 and TBC1D4 are active and cause the hydrolysis of GTP to GDP and inorganic
phosphate rendering Rab proteins inactive. Insulin stimulation results in the
phosphorylation of TBC1D1 and TBC1D4 by AKT2 which inactivates the Rab-GTPases.
Therefore, Rab is bound to GTP and GLUT4 membrane trafficking occurs (Ramm et al.,
2006; Satoh, 2014).
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The signaling prompted by contraction begins in a manner distinct from insulin
signaling. One of the major players in contraction-mediated glucose uptake is the protein
AMP-activated protein kinase (AMPK). This protein is an energy sensor of the cell and
becomes active in conditions of elevated AMP. When AMP is high, it binds AMPK
causing a conformational change that exposes the catalytic domain. Active AMPK then
phosphorylates TBC1D1/TBC1D4 to relieve inhibition of the translocation of GLUT4 by
Rab proteins as described in insulin-signaling. In addition to AMPK, calcium ions and
nitric oxide have also been suggested as contributors to increased glucose uptake with
contractions. During skeletal muscle contraction, intracellular calcium increases and
studies administering small doses of caffeine have shown that increased calcium leads to
increased glucose uptake (Holloszy and Narahara, 1965). However, the mechanism by
which calcium signals in skeletal muscle glucose uptake is still unknown. At this point in
time, it is thought that calcium may work through activation of the calcium/calmodulin
dependent protein kinases. Another possibility is that calcium effects are indirect and
result from changes in AMP levels as the sarcoendoplasmic reticulum (SR) ATPase
hydrolyzes ATP and pumps calcium back into the SR (Richter and Hargreaves, 2013).
Regardless of the initial steps, outcome is inactivation of TBC1D1/TBC1D4 and
translocation of GLUT4 from intracellular stores to the membrane (Figure 1.3).
It is evident that both insulin and contraction stimulation increase GLUT4
translocation and glucose uptake into the skeletal muscle. These signaling pathways are
distinct as they begin signaling through different molecules and it is known that
contraction-mediated glucose uptake can occur in the insulin-resistant condition
(Brozinick et al., 1992; Cheatham and Kahn, 1995; Richter and Hargreaves, 2013). It is
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Figure 1.4. Diagram depicting insulin- and contraction-stimulated glucose uptake. Solid
lines depict known mechanisms while dotted lines depict theorized mechanisms.

particularly important to note however, that despite differences in signaling, insulin- and
contraction-stimulated glucose uptake both require GLUT4.

1.3.3 Skeletal muscle glycolysis
Glycolysis is an essential metabolic pathway in skeletal muscle for utilization of
glucose as fuel. This pathway catabolizes glucose and converts it to pyruvate (in aerobic
conditions) or lactic acid (in anaerobic conditions) while producing a net two ATP and
two NADH. The glycolytic enzymes are present in the cytosol of the skeletal muscle cell,
which is worthy to note since glycolysis helps establish the glucose concentration
gradient between the extracellular space and the cytosol (Boiteux and Hess, 1981;

21

Marieb and Hoehn, 2012). This establishes a precarious link between glycolysis and
glucose uptake. As glucose is taken up into the cell the first step of glycolysis occurs and
glucose is immediately phosphorylated to glucose 6-phosphate by the key glycolytic
enzyme hexokinase 2 (HK2) (Easterby and Qadri, 1982; Ritov and Kelley, 2001). The
prompt phosphorylation of glucose maintains helps maintain glucose at a lower level
inside the cell so that glucose can travel down its concentration gradient into the cell via
GLUT4. If intracellular glucose gets too high, facilitated diffusion of glucose through the
glucose transporter can no longer occur (Fueger et al., 2007). The reaction catalyzed by
HK2 requires energy and therefore the hydrolysis of a molecule of ATP (Hanson and
Fromm, 1965; Easterby and Qadri, 1982). Glucose 6-phophate is converted to fructose 6phosphate, a pentamer sugar, by the enzyme glucose 6-phosphate isomerase/hexoglucose
isomerase (HGI) (James and Notmann, 1973). Fructose 6-phosphate is recognized by a
rate limiting glycolysis enzyme phosphofructokinase (PFK1) and using energy from
hydrolysis of ATP PFK phosphorylates fructose 6-phosphate to fructose 1,6-bisphosphate
(Bauer and Younathan, 1984; Seki et al., 2006). At this point the 6 carbons are split into
two molecules containing 3 carbons each by aldolase. Aldolase breaks fructose 1,6bisphosphate down into dihydroxyacetone phosphate and glyceraldehyde 3-phosphate
(Hearn and Wainio, 1957; Mukai et al., 1984). The dihydroxyacetone phosphate must be
converted into glyceraldehyde 3-phosphate in order to continue on in glycolysis. The
conversion of dihydroxyacetone phosphate to glyceraldehyde 3-phosphate is
accomplished by the enzyme triose phosphate isomerase (Boiteux and Hess, 1981). Both
molecules of glyceraldehyde 3-phosphate are then converted to 1,3-bisphosphate by the
removal of hydrogen catalyzed by 3-glyceraldehyde dehydrogenase. This reduction
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oxidation reaction is coupled to the simultaneous reduction of NAD+ to NADH
(Vospelnikova et al., 1981; Bell et al., 2014). 1,3-bisphosphate is converted to 3phosphoglycerate as 3-phosphoglycerate kinase removes the phosphate from the 2’
carbon position and concomitantly synthesizes ATP from ADP. Two ATP are produced
at this step for every molecule of glucose due to the breakdown of glucose into 3-carbon
chains (Scopes, 1975; Zhou et al., 1991). The phosphate on the 3’ position of 3phosphoglycerate is moved to the 2’ carbon position by phosphoglyceromutase
generating 2-phosphoglycerate (Qiu et al., 2008). The enzyme enolase then catalyzes a
dehydration reaction and phosphoenolpyruvate is obtained as water is removed
(Haralambie and Reinartz, 1978; Merkulova et al., 2000). Pyruvate kinase
dephosphorylates phosphoenolpyruvate to pyruvate while adding the phosphate to ADP
to form ATP. As seen with the reaction a catalyzed by 3-phosphoglycerate kinase, two
molecules of ATP are formed for each glucose catabolized (Baranowska and Baranowski,
1975) (Baranowska and Baranowski, 1977). Pyruvate is the main endpoint of glycolysis
and can either be shuttled into the Kreb’s cycle for oxidative metabolism or can be
reduced to lactic acid by lactate dehydrogenase (Muirhead and Watson, 1992) (Figure
1.5).
The two main regulatory points for glycolysis in the skeletal muscle are the rate
limiting enzymes HK2 and PFK1. HK2 is sensitive to the ratio of glucose 6-phosphate to
glucose and is inhibited when glucose 6-phosphate is high. HK2 can greatly affect
glycolytic rate and glucose uptake. If HK2 activity decreases, glucose will not be
converted to glucose 6-phosphate for further glucose metabolism, and the concentration
gradient promoting the movement of glucose into the cell will be lost
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Figure 1.5. Basic schematic of the glycolytic pathway modified from Karp G, Cellular
and Molecular Biology (2009), (Karp, 2009).

(Kruszynska et al., 1998; Fueger et al., 2007; Dieni and Storey, 2011). PFK1 activity is
allosterically modulated and responds to the ADP:ATP ratio, changes in pH, creatine
phosphate and citrate. PFK1 is often considered the major rate limiting enzyme of the
glycolytic pathway (Tornheim and Lowenstein, 1976). PFK1 and HK2 activity are
critical and decreased activity is often associated with insulin resistance and diabetes
(Bauer and Younathan, 1984; Vestergaard et al., 1993; Sanderson et al., 1996;
Kruszynska et al., 1998; Vestergaard, 1999; Fueger et al., 2007). Due to their significant
impact on glycolytic flux and the role of HK2 in glucose uptake, these two enzymes will
be a focus of this dissertation. The metabolites generated by glycolysis will also be
important.

1.4 The whole picture: circadian rhythms, glucose uptake and glycolysis.
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Circadian rhythms generate the approximate 24 hour oscillations in living
organisms that control physiological functions such as metabolism. These rhythms are
generated by a molecular clock that in mammals consists of core molecular clock genes,
Bmal1, Clock, Per1/2 and Cry1/2 (Shearman et al., 2000; Buhr and Takahashi, 2013;
Robinson and Reddy, 2014). Virtually all cells in the body have a molecular clock that
both acts as a time-keeping mechanism and directs some tissue-specific gene expression
(Panda et al., 2002; Yoo et al., 2004; Kornmann et al., 2007; Shostak et al., 2013;
Hodge et al., 2015b). When the clock mechanism is disrupted it leads to detrimental
effects, one major effect being development of metabolic disease. Studies in clock
disrupted models demonstrate impairments in glucose tolerance, insulin sensitivity, and
body weight and composition (Rudic et al., 2004; Turek et al., 2005; Kondratov et al.,
2006; Scheer et al., 2009; Lee et al., 2013). However, the contribution of tissue-specific
clocks to metabolism is yet unclear. Our lab recently identified 1,628 circadian mRNAs
in skeletal muscle; gene ontology analysis that 62% of those 1,628 mRNAs had
metabolic functions. Furthermore, when looking at changes in gene expression of muscle
from skeletal muscle specific Bmal1 knockout mice we discovered that carbohydrate
metabolism was the most affected process. This suggests a vital role for the skeletal
muscle clock in glucose metabolism (Hodge et al., 2015b).
Glucose metabolism is essential for providing energy for cells and maintaining
homeostasis. Dysfunctions in glucose metabolism can easily lead to metabolic problems
including blood glucose issues, changes in insulin sensitivity, glucose intolerance and
diabetes (Daly, 2003; Marieb and Hoehn, 2012). Skeletal muscle is a crucial metabolic
tissue and accounts for up to 80% of glucose metabolism in the postprandial stated.
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Accordingly, skeletal muscle glucose metabolism has a significant impact on metabolic
health (DeFronzo et al., 1985; Ferrannini et al., 1985). Glucose metabolism involves a
variety of processes: two major processes in skeletal muscle being glucose uptake and
glycolysis. Glucose uptake into skeletal muscle is stimulated by insulin and contraction,
which rely on distinct signaling pathways, but both depend on the skeletal muscle glucose
transporter GLUT4 (Kanai et al., 1993; Deems et al., 1994; Ren et al., 1994; Richter
and Hargreaves, 2013). Skeletal muscle uptake of glucose helps clear blood glucose to
maintain set point (70-110 mg/dL) and provides skeletal muscle with glucose as an
energy substrate. After uptake, glucose can be metabolized by skeletal muscle through
the glycolysis, an 11-12 step pathway involving key enzymes such as HK2 and PFK1
(Boiteux and Hess, 1981).
Our understanding of the skeletal muscle clock’s role in metabolism is limited,
but as stated, loss of the skeletal muscle clock significantly alters expression of mRNAs
involved in carbohydrate metabolism (Hodge et al., 2015b). In addition, a recent study by
Dyar and colleagues provides impelling evidence that the skeletal muscle clock helps
regulate glucose metabolism, as loss of skeletal Bmal1 resulted in impaired glucose
uptake, decreased GLUT4 levels, reduced HK2 levels and diminished PDH activity
(suggesting a possible shift from glucose to fatty acid metabolism) (Dyar et al., 2014).
Much of these results were done solely in a non-inducible model though, so may be
complicated by developmental effects. This dissertation further investigates the impact of
skeletal muscle specific clock dysfunction using our own inducible skeletal muscle
specific Bmal1 knockout mice (iMSBmal1-/-). The aims of the study were to determine
how loss of skeletal muscle Bmal1 affected glucose uptake, glycolytic flux and the
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overall body metabolic phenotype. This was accomplished using a combination of ex
vivo radiolabeled glucose uptake experiments, RT PCR, western blot, enzyme activity
assays, blood analysis, echo-MRI and tolerance tests. Results will be presented
demonstrating impairment in glucose uptake, decreased glycolytic flux and altered
phenotype (e.g. changes in body composition, altered blood glucose/insulin and impaired
glucose tolerance). The data obtained expands our knowledge of skeletal muscle clock
function in glucose metabolism, provides data on inducible muscle specific mice not
included in the Dyar paper and notably demonstrates a more profound metabolic
phenotype compared to the skeletal muscle specific Bmal1 knockout mice in the Dyar
study (Dyar et al., 2014).
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CHAPTER 2: Methods

Ethical Approval
All experimental procedures were done in accordance with the institutional guidelines for
the care and use of laboratory animals and approved by the University of Kentucky
Institutional Animal Care and Use Committee.

Animal Care and Use
Inducible skeletal muscle specific Bmal1 knockout mice were generated as previously
described (Hodge et al., 2015b). We obtained the skeletal muscle specific, tamoxifen
inducible Cre recombinase mouse from the Center for Muscle Biology at the University
of Kentucky. This mouse has a Cre recombinase flanked by two mutated estrogen
receptors and a human skeletal actin promoter. Past work has been published confirming
the efficacy of this mouse for muscle specific gene recombination in adult mice
(McCarthy et al., 2012). The tamoxifen inducible Cre recombinase mouse was crossed
with the Bmal1 floxed mouse acquired through Jackson Labs (B6, 1294(Cg)Arntltm1Weit/J), to generate the inducible skeletal muscle specific Bmal1 floxed mouse
(iMSBmal1fl/fl). After 12 weeks of age, the iMSBmal1fl/fl mice injected intraperitoneally
with 2g/kg of either vehicle or tamoxifen for 5 consecutive days. The age of injection was
chosen in attempt to eliminate any developmental effects. Recombination has been
confirmed and is demonstrated in Hodge et. al (Hodge et al., 2015b). Prior to experiments
mice were housed in 14:10, light:dark conditions. All experiments were performed 5
weeks post-recombination. All experiments, with the exception of the non-fasting blood
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glucose, behavior measurements and echo-MRI, were done 2 hours after the lights turned
off. This time was chosen due to the fact that glucose tolerance is higher in the beginning
of the active phase (la Fleur et al., 2001). Both genders were used with a higher ratio of
male to female mice. Echo-MRI was also performed at 12 weeks post-recombination.
Mice were euthanized prior to glucose uptake experiments and tissue collections.
Euthanization was done by anesthetizing mice with isoflurane followed by cervical
dislocation.

Echo-MRI
Body composition was quantified in conscious mice at both 5 and 12 weeks postrecombination using EchoMRI Quantitative Magnetic Resonance Body Composition
Analyzer (Echo Medical Systems, Houston, Texas) (n=7/group). Before body
composition analysis, mice were weighed. Conscious mice were then placed into a
measuring tube of appropriate size and the tube was placed into the Echo-MRI machine
which provided data on fat mass, lean mass and water mass through detection of
distinctions in NMR amplitudes of the different tissues.

Glucose tolerance test
Glucose tolerance tests (n=8) were performed two hours after lights turned off, a time at
which glucose tolerance is highest (la Fleur et al., 2001). Mice were fast six hours prior to
the start of the test and all measurements were done with an AlphaTrak glucometer
(Abbott Animal Health). A measurement was taken prior to injection of a bolus of
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glucose (0 minutes). Mice were injected intraperitoneally with 2mg/kg glucose and
additional measurements were taken at 15, 30, 60, 90, and 120 minutes post-injection.

Insulin sensitivity assays
Mice were fasted for six hours prior to tests, such that the start of the experiment
coincided with zeitgeber time 14 (two hours past lights out) (n=8). Three different doses
of insulin were tested: a submaximal dose of 0.75 U/kg, a maximal dose of 1.0 U/kg and
an intermediate dose of 0.85 U/kg. At the start of the experiment (time point 0), the tail
vein was nicked and blood glucose was measured using an AlphaTrak glucometer. Mice
were then injected with the appropriate dose of Humulin R-100 insulin. Blood glucose
was monitored by further measurements at 15, 30, 45 and 60 minutes post injection. If
blood glucose dropped below 70 mg/dL or mice began showing signs of low blood
glucose, they were immediately injected with a bolus of dextrose.

Blood measurements
All fasting blood measures were obtained after a 6 hour fast. Fasting blood glucose (n=8)
was measured with the AlphaTrak glucometer and fasting insulin (n=7/group) was
measured by collecting blood from the tail vein of the mice and running a colorimetric
ELISA (Crystal Chem). Non-fasting blood glucose was measured by measuring blood
glucose every 4 hours for 24 hours and averaged (n=4 per time point).

Glucose uptake experiments
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All solutions in this experiment were bubbled with 95%O2/5%CO2 and kept at 35°C.
Extensor digitorum longus muscles were excised from each leg of the mice and placed in
a recovery media (Krebs Henseleit Buffer (KHB) with 0.1% bovine serum albumin, 2
mM sodium pyruvate, 6 mM mannitol) with or without 2,000 µU/mL insulin. After 30
minutes, muscles were transferred to an incubation buffer (KHB with 0.1% bovine serum
albumin, 2 mM sodium pyruvate, 6mM mannitol, 1 mM 2-deoxy-D-glucose, 2.25 µL/mL
[3H]-2-deoxyglucose, 2 µL/mL [14C]-mannitol) with or without 2000 µU/mL insulin
(consistent with what the muscle was exposed to in recovery media) for exactly 20
minutes. After 20 minutes, tissues were flash frozen. Tissue lysates were prepared and
100 µL of each sample was added to a scintillation vial with 5 mL of scintillation fluid
followed by radioactivity measurement in a scintillation counter.

Real time PCR (RT-PCR)
RNA was isolated from gastrocnemius samples of iMSBmal1+/+ and iMSBmal1-/- mice
(n=7/group). Briefly, 50-100 mg of gastrocnemius tissue was homogenized in 1 mL
Trizol (Invitrogen). Phase separation, RNA precipitiation and RNA washes and RNA
redissolving were carried out as per manufacturer’s instructions. RNA was quantified
through spectrophotometry with wavelength, λ = 260 nm. Total RNA was then used to
synthesize cDNA using a mixture of oligo(dT) primer and random hexamers in
SuperScript III First-Strand Synthesis SuperMix (Invitrogen, Waltham, MA, USA) kit.
Expression of Glut4, Hk2, and Pfk1 was done using cDNA and the following Taqman
primers: Mm01245502_m1, Mm00443385_m1, Mm01309576_m1, Mm99999915_g1
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and Mm02343715_g1. Gene expression was determine using the 2^-ΔΔCT method and all
target genes were normalized using Gapdh or Rpl26.

Circadian Microarray
Inducible skeletal muscle specific mice (iMSBmal1+/+ and iMSBmal1-/-) were housed in
light boxes and entrained to a 12:12 light dark cycle for five weeks. During this
experiment mice were given ad libitum access to both food and water. 30 hours prior to
the start of collections, mice were released into constant darkness. Samples (including
gastrocnemius muscle, liver and blood) were collected every 4 hours for 28 hours. RNA
was isolated from gastrocnemius samples as previously described. Equal amounts of
RNA was pooled from the four mice in each group at each time point. cDNA libraries
were generated from the pooled RNA samples and these libraries were then hybridized to
Affymetrix mouse gene 1.0 ST microarrays (Affymetrix, Santa Clara, CA). Relative
intensity values were obtained and analyzed as described in Hodge et.al., 2015 (Hodge et
al., 2015b).

Western blot analysis
Tissue lysates were made from gastrocnemius muscles of iMSBmal1+/+ and iMSBmal1-/mice. Proteins were separated by SDS-PAGE using 4-15% Tris-HCl precast gels
(BioRad), transferred and immunoblotted using routine methods. GLUT4 was detected
using a primary monoclonal GLUT4 antibody (Cell Signaling, #2213) and an
AlexaFluor680 goat anti-rabbit secondary antibody (Invitrogen, #A-21109).
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Hexokinase activity assay
Hexokinase activity was measured following as previously described.(Scheer et al., 1978)
Gastrocnemius tissue (n=7/group) was homogenized in a buffer (1:10, weight:volume)
containing 150 mM KCl, 10 mM MgCl2, 5 mM EDTA and 5 mM β-mercaptoethanol.
Samples were centrifuged at 15,000xg for 1 hour while experimental solutions, A (47
mM Tris (pH 7.4), 10 mM MgCl2, 0.8 mM NADP, 0.5 mM glucose, 5.0 mM
mercaptoethanol, 0.1 units glucose 6-phosphate dehydrogenase), and B, were
prepared(47 mM Tris (pH 7.4), 10 mM MgCl2, 0.8 mM NADP, 0.5 mM glucose, 5.0 mM
mercaptoethanol, 0.1 units glucose 6-phosphate dehydrogenase, 5 mM ATP, 0.27 mM
phosphoglyceric acid). An eppendorf tube containing 2.45 mL of A or B was made for
each tissue sample. After centrifugation was complete, 0.05 mL of tissue sample was
added to each tube. Absorbance was measured at 30°C and 340 nM every 2 seconds for
10 minutes. Samples were measured in duplicate. As the glycolytic reaction takes place,
NADP is oxidized to form NADPH which has an absorbance at 340 nm. Activity is
shown as µM/g/min (micromole NADPH formed per gram of tissue per minute)

Phosphofructokinase activity assay
The same tissue samples used for the hexokinase activity assay were used for the
phosphofructokinase assay but a different reaction mixture/solution was used. The
reaction mixture for this assay contained 50 mM Tris-HCl (pH 8), 1 mM EDTA, 6 mM
MgCl2, 2.5 mM dithiothreitol, 0.16 mM NADH, 1 mM ATP, 1 mM fructose-6phosphate, 0.4 units aldolase, 2.4 units triose-phosphate isomerase and 0.4 units α–
glycero-phosphate dehydrogenase. 5 µL of tissue sample was added to 295 µL of reaction
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mixture and absorbance was read at 25°C and 340 nM for 10 minutes. As the glycolytic
reaction takes place, NADH, which is detectable at 340 nm, is reduced to NAD+ and
absorbance decreases. Activity is shown in U/g/min (where U is enzyme activity based
upon the reduction of NADH).

Glycogen Assays
Glycogen concentrations were determined for gastrocnemius tissue and liver using
samples from the circadian time course collection (n= 32). Approximately 30-50 mg of
tissue was cut and weighed. Samples were immersed in 1 mL of 30% KOH saturated
with Na2SO4 and boiled at 95°C for 20-30’ until complete digestion. Boiled samples were
vortexed and placed on ice until cool. Glycogen was then precipitated by adding 2 mL of
95% ethanol. Precipitated samples were vortexed and incubated another 30 minutes on
ice. After the incubation, samples were centrifuged at 550Xg for 30 minutes. The
supernatant was decanted and the tubes were dried upside down for five minutes or until
dry. The pellet was redissolved in 1 mL of water and vortexed until completely in
solution. A milliliter of 5% phenol was added followed by 5 mL of 96% H2SO4. The
mixture was incubated on ice for 30 minutes as color developed and then absorbance was
read at 490 nm. Concentrations were determined using a concentration curve with
glycogen standards (0, 25, 50, 75 and 100 g/ml glycogen).

Metabolomics data
Gastrocnemius muscles were obtained from anesthetized mice using liquid nitrogen
cooled clamps. Tissue was immediately flash frozen and labeled gastrocnemius samples
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were sent to University of Michigan Metabolomics Core Services for processing. For
metabolomics, 20mg of gastrocnemius tissue was ground up and transferred to a
microtube containing isotope-labeled internal standards and a mixture of methanol,
chloroform and water (8:1:1). Samples were sonicated (40% power output, 20% duty
cycle, 20 seconds), chilled (4°C, 10 minutes) and centrifuged (4°C, 14,000 RMP, 10
minutes). Liquid chromatography-mass spectrometry analysis was performed on an
Agilent system with a 1260 UPLC module coupled to a 6520 Quadrupole Time-of-Flight
spectrometer (Agilent Technologies, CA). Data obtained was processed with MassHunter
Quantitative Analysis version B.07.00. Sample data was normalized to the nearest
isotope-labeled standard.

Statistics
For statistics on blood concentrations, glucose tolerance, RT-PCR, body composition,
behavior and enzyme activities and student t-test was utilized. 2-way ANOVA was used
to evaluate data from glucose uptake experiments (comparing time exposed to insulin and
genotype). Metabolites from the glycolytic pathway were analyzed using a Hotelling’s Tsquared test to identify if metabolites within the same pathway were changed between
iMSBmal1+/+ and iMSBmal1-/- mice.
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Chapter 3: Results

Previous studies in Bmal1 knock out mouse models have demonstrated that loss
of Bmal1 significantly affects systemic metabolic parameters (Rudic et al., 2004;
Kennaway et al., 2013). In order to assess the contribution of the molecular clock in
skeletal muscle to systemic metabolic homeostasis, we generated an inducible skeletal
muscle specific Bmal1 knock out mouse (iMSBmal1-/-; following tamoxifen treatment)
for the targeted disruption of the molecular clock mechanism only in adult skeletal
muscle.(Hodge et al., 2015a) As early as 5 weeks post-treatment, iMSBmal1-/- mice
demonstrated an increase in lean composition and a trend towards reduced fat
composition relative to iMSBmal1+/+ (Figure 3.1A). These changes became more
pronounced at 12 weeks post treatment, at which point, iMSBmal1-/- mice were leaner,
had less fat composition and displayed an overall decrease in body weight compared to
iMSBmal1+/+ mice (Figure 3.1B). These changes in body composition could not be
attributed to altered feeding or behavior, as there were no detectable differences in net
feeding or net activity in the iMSBmal1-/- mice (Figure 3.1C). The observed changes in
body composition, coupled with the lack of difference in net feeding and activity,
suggested differences in metabolic fuel usage. For this reason, we performed glucose
tolerance tests, as well as, assessed blood glucose and insulin. Fasting blood glucose
(Figure 3.2A) was not significantly different between groups, but iMSBmal1-/- mice had
elevated fasting insulin levels compared to iMSBmal1+/+ mice (Figure 3.2B). When
injected with a bolus of exogenous glucose, iMSBmal1-/- mice exhibited a greater overall
increase in blood glucose. In addition, glucose levels
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Figure 3.1. Body composition (including body weight, % lean mass, % fat mass and
%water weight) and behavior (including net feeding and net activity) are shown for the
iMSBmal1+/+ and iMSBmal1-/- mice. (A) Body weight and composition in mixed genders
at 5 weeks post-recombination (n=13 iMSBmal1+/+, n=18 iMSBmal1-/-). (B) Body weight
and composition for exclusively male mice at 5 weeks post-recombination (n=13
iMSBmal1+/+, n=16 iMSBmal1-/-). (C) Body weight and composition at 12 weeks postrecombination (n=6 iMSBmal1+/+, n=7 iMSBmal1-/-). (D) Feeding and activity over 4
days at approximately 5 weeks post-recombination (n=4 iMSBmal1+/+, n=6 iMSBmal1-/-).
remained elevated for a longer period of time in the iMSBmal1-/- mice. The combination
of the overall increase in blood glucose, and the extended time that blood glucose
remained elevated in the iMSBmal1-/- mice, significantly increased area under the curve
when compared to the control mice (iMSBmal1+/+) (Figure 3.2C). We carried out a
circadian time course collection with vehicle and tamoxifen-treated mice. Blood from
iMSBmal1+/+ and iMSBmal1-/- mice were collected every 4 h over a 28-h period, and
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non-fasting blood glucose was measured. When blood glucose was measured in the nonfasting state, iMSBmal1-/- displayed significantly higher blood glucose values over a 24
hour period of time relative to iMSBmal1+/+ mice (Figure 3.2D).
Skeletal muscle is the major site for glucose disposal in the postprandial state. The
measured glucose intolerance and elevated non-fasting blood glucose levels implied a
defect in skeletal muscle glucose uptake. We examined this further by measuring both
insulin-stimulated and 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR)stimulated glucose uptake in the extensor digitorum (EDL) muscles of iMSBmal1+/+ and
iMSBmal1-/- mice. Both insulin and muscle contraction have been demonstrated to
stimulate glucose uptake into the skeletal muscle. AICAR allows for the examination of
contraction stimulated glucose uptake. We found that insulin-stimulated glucose uptake
was significantly impaired in the iMSBmal1-/- mice (Figure 3.3A). When EDL muscles
were stimulated with AICAR in place of insulin, iMSBmal1-/- still exhibited a significant
decrease in glucose uptake (Figure 3.3B).
Insulin and AICAR stimulate separate pathways. However, our results indicated
that a component essential to both pathways contributed to the observed impairment of
glucose uptake. Both pathways rely on the translocation of the glucose transporter
(Glut4) to the plasma membrane to allow transport of glucose from blood into the cell. In
the iMSBmal1-/-, both mRNA expression and protein content of the glucose transporter
were dramatically reduced relative to that measured in iMSBmal1+/+ mice (Figure 3.4
A,B).
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Figure 3.2. Fasted blood glucose and insulin, glucose tolerance and non-fasted blood
glucose for the iMSBmal1+/+ and iMSBmal1-/- mice at 5 weeks post-recombination. (A)
Fasted blood glucose (n=8). (B) Fasted blood insulin (n=7/group). (C) Glucose tolerance
depicted as blood glucose versus time post-glucose injection and area under the curve
(n=8). (D) Non-fasted blood glucose measured every 4 hours for 24 hours (n=24). Gray
blocks indicate the active phase and white areas indicate the inactive phase.

Figure 3.3. Glucose uptake (both insulin- and AICAR-stimulated) in the iMSBmal1+/+
and iMSBmal1-/- mice. (A) Insulin stimulated glucose uptake in the EDL muscles using a
maximum insulin dose and 20 minutes of exposure (n=8). (B) AICAR stimulated glucose
uptake in the EDL muscles after 40 minutes of exposure incubation media with or
without AICAR (n=5).
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Figure 3.4. mRNA expression and protein content of the glucose transporter type 4
(Glut4/GLUT4) in the iMSBmal1+/+ and iMSBmal1-/- mice. (A) mRNA expression of
Glut4 in the gastrocnemius muscle measured using RT PCR and calculated via the 2(ΔΔCT)
method (n=6). (B) Protein content of GLUT4 in the gastrocnemius muscle was
measured as integrated intensity (I.I. counts) of the fluorescent bands (n=7/group).

Upon entering the cell, glucose is phosphorylated to glucose-6-phosphate by the
glycolytic enzyme hexokinase 2 (HK2). This transformation of glucose allows the cell to
maintain a glucose gradient relative to the extracellular fluid to sustain glucose influx. In
this regard, HK2 activity may affect glucose uptake. Microarray analysis was done on
gastrocnemius tissue from the aforementioned circadian time course collection. Signal
intensity measured for Hk2 mRNA was significantly lower in the iMSBmal1-/- mice
(Figure 3.5A). This suggests lower expression of Hk2 in the iMSBmal1-/- mice which is
consistent with the decreased protein content demonstrated in the Dyar study (Dyar et al.,
2014). This does not however, indicated activity levels of the HK2 enzyme so we went a
step further and measured HK2 activity in the gastrocnemius muscles of the
iMSBmal1+/+ and iMSBmal1-/- mice. HK2 was found to have significantly reduced
enzymatic activity in iMSBmal1-/- mice providing strong evidence that glucose
phosphorylation is diminished (Figure 3.5B). Besides having an impact on glucose
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uptake, HK2 is a rate limiting enzyme in the glycolytic pathway. In order to further
evaluate glycolytic flux in the iMSBmal1-/- mice, we examined another rate limiting
enzyme of glycolysis, phosphofructokinase (PFK1). Pfk1 mRNA expression was
reduced in iMSBmal1-/- mice and PFK1 activity was significantly reduced as well
(Figure 3.5 C, D). To further examine glycolytic flux we assessed metabolite profiles in
the gastrocnemius of the iMSBmal1+/+ and iMSBmal1-/- mice. Metabolomics data
revealed elevated glucose within the muscle of the iMSBmal1-/- mice compared to the
iMSBmal1+/+ mice (Figure 3.6A). Excess glucose is stored in muscle as the multibranched, polysaccharide glycogen. Consistent with the observed increased muscle
glucose from the metabolomics data we observed an increase in glycogen in the
gastrocnemius muscle of the iMSBmal1-/- mice (Figure 3.6B). This suggests that glucose
is being stored in skeletal muscle rather than being oxidized. This data is congruous with
the observed decrease in activity of rate-limiting glycolytic enzymes, PFK1 and HK2, but
to strengthen our investigation we also looked at glycolytic metabolites. Two glycolytic
metabolites, glyceraldehyde 3-phosphate and phosphoenolpyruvate trended to be lower
while both 2- and 3-phopshoglycerate displayed a significant reduction in the iMSBmal1/-

mice. We evaluated glycolytic metabolites from the microarray dataset as a group

within each genotype using the Hotelling’s t-squared test for independent samples.
Results indicated that as a group, these metabolites were significantly decreased in the
iMSBmal1-/- mice relative to iMSBmal1+/+ mice (Figure 3.6C). This evidence reinforces
the idea that oxidation of glucose is diminished in the skeletal muscle of iMSBmal1-/mice.
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Figure 3.5. Activity of rate-limiting glycolytic enzymes (HK2 and PFK1) in the
iMSBmal1+/+ and iMSBmal1-/- mice. (A) mRNA expression of Hk2 obtained from
microarray data (n=6). (B) Enzymatic activity of the rate limiting enzyme HK2 in the
gastrocnemius muscle measured using a spectrophometric assay (n=7/group). (C) mRNA
expression of the rate limiting enzyme Pfkm in the gastrocnemius muscle (n=7/group).
(D) Enzymatic activity of PFKM in gastrocnemius muscles.
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Figure 3.6. Glycolytic flux is altered in the iMSBmal1-/- mice. (A) Metabolomics
analysis of glucose in the GTN of iMSBmal1+/+ and iMSBmal1-/- mice. Glucose
(measured as peak area) is significantly increased in the skeletal musle of iMSBmal1-/mice (n=7/group). (B) Glycogen content in the GTN of iMSBmal1+/+ and iMSBmal1-/mice measured via colorimetric assay (n=32). (C) Metabolites of glycolysis from the
metabolomics dataset in the iMSBmal1+/+ and iMSBmal1-/- mice (n=7/group). (D)
Schematic showing effect of Pdk4 and Pdp1 on glucose oxidation. Percentages are the
change in intensity signal relative to iMSBmal1+/+ mice obtained from microarray
analysis. Green depicts changes in the positive direction (increased) and red depicts
changes in the negative direction (decreased).
The data presented thus far provides compelling evidence that iMSBmal1-/- mice
have altered skeletal muscle glucose metabolism. Glycolytic flux appears to be
decreased, glucose uptake is significantly impaired, glucose tolerance is reduced and
body composition changes in an age-dependent manner. Additional experiments were
done however that resulted in confounding data. Since skeletal muscle insulin stimulated
glucose uptake was significantly impaired and iMSBmal1-/- mice were glucose intolerant,
it was hypothesized that insulin sensitivity would be lower in the iMSBmal1-/- mice.
Three different doses were tested, 0.75 U/kg, 0.85U/kg and 1.0 U/kg and were referred to
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as submaximal, intermediate and maximal respectively. The first dose examined was the
submaximal dose. When iMSBmal1+/+ and iMSBmal1-/- mice were injected with this
dose, no significant difference was detected (Figure 3.7A). In contrast, when mice were
given the intermediate or maximal dose, blood glucose dropped lower in the iMSBmal1-/mice and remained decreased for a longer amount of time (Figure 3.7 A,B). For the
intermediate dose it is important to note that four of the eight iMSBmal1-/- mice dropped
to critical blood glucose values (below 70 mg/dL) and began to seize around 30 minutes
post-injection. As a result, these mice had to be given emergency doses of glucose and
were omitted from the later timepoints. As one might expect, the maximal dose had an
even more severe effect and the experiment was stopped 30 minutes post-injection do to
the presence of seizures in the iMSBmal1-/- mice. These insulin tolerance tests suggest
that the iMSBmal1-/- mice are actually more insulin sensitive compared to iMSBmal1+/+
mice. Insulin sensitivity is not solely determined by skeletal muscle glucose metabolism.
Other metabolic tissues such as the liver and adipose may contribute to glucose uptake
and are quite important for counterregulatory responses (such as glycogenolysis,
gluconeogenesis and hormone release) to insulin. In fact, liver glycogenolysis has been
shown to account for approximately 90% of endogenous glucose production in healthy
subjects (Kishore et al., 2006). Glycogenolysis is the breakdown of glycogen to glucose
and therefore the extent to which glucose can be mobilized is dependent on glycogen
content. We measured hepatic glycogen in liver tissue from the circadian time course
and found that liver glycogen was significantly reduced in the iMSBmal1-/- mice (Figure
7D). This may indicate that iMSBmal1-/- mice cannot respond appropriately to insulininduced hypoglycemia, accounting for at least some part of the significant drop in blood
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Figure 3.7. Insulin tolerance tests (n=8) and liver glycogen (n=32) in the iMSBmal1+/+
and iMSBmal1-/- mice. (A) Insulin tolerance test using the submaxiaml dose of 0.75 U/kg.
(B) Insulin tolerance test with an insulin dose of 0.85 U/kg (# indicates the point at which
4 mice were dropped from experiment due to hypglycemic seizures). (C) Insulin
tolerance test using a maximal dose of 1.0 U/kg insulin. Test only goes to 30 minutes
post-injection due to severe hypoglycemic symptoms in the iMSBmal1-/- mice. (D)
Liverg glycogen in the iMSBmal1+/+ and iMSBmal1-/- mice.

glucose observed in iMSBmal1-/- mice following intermediate and maximal insulin doses.
Interestingly, this also implies that knockdown of Bmal1 exclusively in skeletal muscle
has an effect on another (Bmal1 postive) tissue (liver). Further research is required in
order to determine other factors that contribute to the insulin sensitivity in the iMSBmal1/-

mouse and the mechanism by which skeletal muscle is affecting other tissues. Overall

however, it is clear from the data that the inducible loss of Bmal1 in skeletal muscle has a
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substantial effect on skeletal muscle glucose metabolism. Therefore, it can be concluded
that Bmal1 and circadian rhythms have an essential role in regulating skeletal muscle
glucose metabolism.
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Chapter 4: Discussion

4.1. Discussion of Data
Skeletal muscle is a fundamental metabolic tissue and primarily responsible for
the disposal of glucose in the postprandial state (Ferrannini et al., 1988). Circadian
rhythms play an important role in regulating metabolism in a tissue specific manner and
recent research demonstrates that disruption of circadian rhythms leads to metabolic
dysfunction and disease (Storch et al., 2002; Schmutz et al., 2012; Dyar et al., 2014;
Hodge et al., 2015b). Our understanding of the function of the clock and core clock
genes, such as Bmal1, in skeletal muscle is still quite elementary. In our investigation we
demonstrated that loss of the circadian core clock gene, Bmal1, in exclusively skeletal
muscle results in: impaired glucose uptake with concomitant reduction in the muscle
glucose transporter GLUT4, decreased glycolytic flux with a potential shift in substrate
utilization, hyperglycemia in the non-fasting condition, glucose intolerance and changes
in overall body composition.
Dyar et. al. previously showed that loss of skeletal muscle Bmal1 resulted in
impaired insulin-stimulated glucose uptake (Dyar et al., 2014). We expanded on this by
showing that not only is insulin-stimulated glucose uptake impaired, but AICARstimulated glucose uptake is diminished as well. AICAR signals through the same
pathway as contraction, which is distinct from insulin signaling (Brozinick et al., 1992;
Sakamoto and Goodyear, 2002). The pathways do have some common components, one
of which is the glucose transporter GLUT4. Both insulin- and AICAR- stimulated
signaling result in the translocation of GLUT4 from intracellular vesicles to the plasma
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membrane where it can transport glucose into the cell. We found that Glut4 mRNA
expression was significantly decreased in the iMSBmal1-/- mice. We also observed a
significant reduction in GLUT4 protein content which is consistent with GLUT4 protein
data in the Dyar et. al. study (Dyar et al., 2014).
Glucose uptake can also be affected by HK2 activity. HK2 phosphorylates
glucose when it enters the cell thereby maintaining a concentration gradient so that
glucose may passively enter the cell by facilitated diffusion via GLUT4 (Osawa et al.,
1995; Osawa et al., 1996; Fueger et al., 2003; Wasserman et al., 2011; Richter and
Hargreaves, 2013). We observed as decrease in Hk2 expression in our microarray data
which is consistent with the decrease in HK2 protein content reported by Dyar and
colleagues (Dyar et al., 2014). More notably, we measured enzymatic activity and
observed a significant reduction in HK2 activity in iMSBmal1-/- mice. This is important
to point out because although HK2 protein content has been previously reported, total
HK2 enzymatic activity was unknown. The decrease in HK2 activity likely contributes to
the decrease in glucose transport. In fact, a study by Fueger et. al. in 1995 demonstrated
that partial Hk2 knockdown was enough to result in a decrease in an impairment in
glucose uptake (Fueger et al., 2003).
HK2 is a key enzyme of the glycolytic pathway and therefore crucial for
carbohydrate metabolism. A previous publication from our lab evaluating microarray
data suggests that one of the key functions affected by loss of skeletal muscle Bmal1 is
carbohydrate metabolism. The study shows that a number of genes important for
carbohydrate metabolism display decreased expression (Hodge et al., 2015b). The HK2
data from this dissertation provides initial data supporting this idea. We explored this
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further by looking at the other critical glycolytic rate-limiting enzyme PFK1 (Crabtree
and Newsholme, 1972; Nakajima et al., 2002). Both Pfk1 mRNA expression and PFK1
enzyme activity were significantly reduced in the iMSBmal1-/- mice. Taken together, the
decrease in expression and dampening of activity of these two rate-limiting enzymes
presents strong evidence for impaired glucose catabolism and glycolytic flux.
Metabolomics data was obtained for the gastrocnemius muscle of iMSBmal1+/+
and iMSBmal1-/- mice and provided additional data on changes in skeletal muscle
metabolism. In comparing peak areas from the metabolomics data set, we observed
further evidence of reduced glycolytic flux. Muscle glucose content was significantly
higher, while many glycolytic metabolites showed a trend toward or significant decreases
in the iMSBmal1-/- mice relative to the iMSBmal1+/+ mice. Glyceraldehyde 3-phosphate
and phosphoenolpyruvate trended lower while 2-phosphoglycerate and 3phosphoglycerate were significantly decreased. To add to our understanding of glucose
handling we conducted colorimetric assays to measure glycogen content and showed
significantly increased muscle glycogen. These data suggest that glucose is not being
sufficiently utilized in skeletal muscle and is instead being stored.
In light of the fact that skeletal muscle, a vital metabolic tissue, cannot efficiently
dispose of glucose and utilize it as a fuel source, one can expect that this will affect
overall metabolic health. Skeletal muscle is a critical depot for glucose in the postprandial
state, so with impaired glucose uptake it is logical that non-fasting blood glucose would
be elevated. The glucose being consumed would normally trigger insulin release which
would act on tissues (mainly skeletal muscle) to stimulate glucose uptake, but this
process is defective in the iMSBmal1-/- mice. Fasting glucose is not changed in our mice
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but this is possibly because in the fasting state the mice have time to clear the glucose
through uptake into other metabolic tissues. Or perhaps a small amount of glucose is
taken up into skeletal muscle but at a much slower rate. The impairment in glucose
uptake and oxidation also helps explain the glucose intolerance in the iMSBmal1-/- mice.
In a normal glucose tolerance test one would expect the exogenous bolus of glucose to
cause insulin release resulting in increased glucose uptake. Since iMSBmal1-/- mice have
impaired skeletal muscle insulin-stimulated glucose uptake, they do not respond
appropriately to the bolus of glucose. Instead blood glucose goes up much higher and
takes a longer amount of time to be cleared.
The metabolic phenotype observed in the iMSBmal1-/- mice is congruent with
results reported in past literature using partial or full knockout models of Glut4, Hk2 and
Pfk1. A 2000 study examining the effect of muscle specific Glut4 knockout showed that
the mice gained weight more slowly and had reduced fat stores (Zisman et al., 2000).
This is consistent with the decrease in body fat composition observed in our mice. This
same study and some studies on hexokinase- and phosphofructokinase-deficient mice
demonstrate development of insulin resistance, glucose intolerance and elevated blood
insulin (Zisman et al., 2000; Nakajima et al., 2002; Fueger et al., 2003). Loss of Bmal1
in the skeletal muscle of our mice led to deficiencies in the expression and/or activity of
Glut4, Hk2 and Pfk1 and as such, the observed glucose intolerance, increased non-fasting
glucose and elevated insulin are in agreement with past studies. One interesting fact to
note is that where we saw glucose intolerance following skeletal muscle specific Bmal1
knockout, the Dyar study did not. However, this could be due to differences in the ages at
which mice were injected with tamoxifen. We waited to inject our mice with tamoxifen
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until 12 weeks of age. This was done to avoid developmental factors. During
development, satellite cells (which are normally quiescent) may fuse into muscle to
contribute to growth. The inducible model used by our lab and the Dyar study does not
knock down Bmal1 in satellite cells. Therefore, if satellite cells fuse in it results it can
result in partial rescue of Bmal1. The Dyar study injected their mice at an earlier age and
therefore the mice may have had satellite cell fusion and only be partial knockouts. This
may account for the differences reported for glucose tolerance. It is also important to
point out that while the Dyar paper published data demonstrating impaired insulinstimulated glucose uptake in their inducible skeletal muscle Bmal1 knockout model, the
rest of the data in this dissertation is novel. Dyar and colleagues did not investigate other
methods of glucose stimulation. Furthermore the GLUT4, HK2, blood glucose and
metabolomics data presented by Dyar was not done in the inducible knockout model.
Therefore, although many of findings in dissertation were consistent with findings in the
muscle specific knockout mice Dyar used, they are important findings because they
demonstrate that changes in GLUT4, HK2, blood glucose and metabolomics are not to
developmental effects of skeletal muscle Bmal1 deficiency (Dyar et al., 2014).
It is quite clear that glucose uptake and glucose oxidation in skeletal muscle is
impaired in the iMSBmal1-/- mice. Based on these findings it was expected that insulin
sensitivity would be reduced as well. Remarkably, when iMSBmal1-/- mice were tested
with the higher doses of insulin, they showed improved sensitivity to insulin. Blood
glucose levels in the iMSBmal1-/- mice dropped lower and remained lower for a longer
period of time relative to iMSBmal1+/+ mice. Some iMSBmal1-/- mice even went into
seizures and required a bolus of glucose. This was completely unexpected since the
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skeletal muscle presented as insulin resistant. There are two things in the insulin response
curve that be addressed. First is the fact that blood glucose dropped lower at higher doses
of insulin in the iMSBmal1-/- mice relative to iMSBmal1+/+ mice. Since insulin-stimulated
uptake is impaired in the iMSBmal1-/- mice, one possible explanation is that other
metabolic tissues, such as the liver and adipose tissue, are compensating and have
increased insulin sensitivity or glucose uptake. The second part of the response curve that
requires some consideration is the delayed recovery of normal blood glucose levels in the
iMSBmal1-/- mice. When blood glucose drops to low levels, a number of things generally
happen to negatively regulate glucose levels. As glucose levels begin to drop, pancreatic
beta cell release of insulin decreases and glucagon release from the alpha cells increases.
As blood glucose drops below 70 mg/dL, the adrenal medulla is stimulated to secrete the
catecholamines epinephrine and norepinephrine. Two other hormones released are
growth hormone and cortisol. Glucagon, epinephrine, norepinephrine, growth hormone
and cortisol have anti-insulin effects and work to increase blood glucose levels. They
stimulate gluconeogenesis and glycogenolysis thereby generating and mobilizing glucose
(Sprague and Arbelaez, 2011; Marieb and Hoehn, 2012). Liver glycogenolysis is
responsible for approximately 90% of endogenous glucose production in healthy subjects
(Kishore et al., 2006). Our liver glycogen assay showed that liver glycogen stores were
significantly decreased. With reduced liver glycogen, the ability of the liver to deliver
glucose may be diminished. Interestingly, Kishore and colleagues have demonstrated that
intensively treated diabetics may present with defective counterregulation due to inability
of the liver to increase glycogenolysis in response to hypoglycemia. Although are mice
are not intensively treated diabetics, they do present with significantly increased blood
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insulin which might be considered similar to intensive insulin treatment in diabetic
patients (Kishore et al., 2006).
Despite unexpected results for insulin tolerance assays, this investigation reveals
some exciting new findings. Studies evaluating the role of the circadian clock and clock
genes in skeletal muscle metabolism are limited. Past research has shown that insulinstimulated glucose uptake is impaired and GLUT4 protein and HK2 protein are down
(Dyar et al., 2014). The data in this dissertation confirms those finding but goes even
further in elucidating Bmal1 function in skeletal muscle metabolism. The current study
demonstrates that not only is insulin-stimulated glucose uptake impaired but AICARstimulated uptake is defective as well. These two types of glucose uptake signal through
different pathways but share a common endpoint of GLUT4. We confirmed that GLUT4
protein content was reduced and showed that mRNA expression was also reduced. We
showed that Hk2 expression was decreased and went a step further than the Dyar study
and demonstrated that HK2 enzyme activity was reduced (Dyar et al., 2014). Our data
exhibits that the other rate limiting glycolytic enzyme, PFK1, has reduced enzyme and
reduced mRNA expression. This suggests glycolytic activity is down and we showed that
glycolytic metabolites are lower. Glycogen however was increased indicating glucose is
stored in skeletal muscle in lieu of being oxidized. Based on these results at the level of
the skeletal muscle we expected changes in overall metabolic health. In contrast to the
Dyar paper, we presented evidence of glucose intolerance in skeletal muscle Bmal1
knockout mice (Dyar et al., 2014). Our experiments produced data displaying increased
non-fasting glucose and elevated fasting plasma insulin. Furthermore, by 12 week postrecombination we observed significant changes in body composition. Taken together
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these data reveal a crucial role for skeletal muscle Bmal1 in the regulation of skeletal
muscle metabolism and overall metabolic health. Additionally, the insulin tolerance and
more notably the liver glycogen results imply that skeletal muscle Bmal1 and metabolism
may affect the metabolic function of other tissues such as the liver. This is exciting novel
data that advances our current knowledge of skeletal muscle circadian rhythms
(especially core clock gene Bmal1) and metabolism.

4.2 Future experiments
Although this study is important in highlighting a novel role for Bmal1 in
regulating insulin- and AICAR-stimulated glucose uptake, glucose oxidation and
metabolic health, there is still much that is unknown. Further research is required to
elucidate the exact mechanism by which Bmal1 alters GLUT4 content, glucose uptake,
and glycolytic gene expression and activity in skeletal muscle. There are a variety of
metabolic transcription factors that present with circadian expression patterns so it may
be of value to start by evaluating the impact of Bmal1 knockdown on expression of these
transcription factors. For instance, Sp1 and the PPARs have been shown to regulate Glut4
transcription (Marin-Juez et al., 2013). Sp1 and Ppard have e-box sequences that could
be bound by CLOCK:BMAL. In addition, Sp1 and Pgc1a (a coactivator for the PPARs)
have been demonstrated to be regulated in some part by circadian rhythms (MendezFerrer et al., 2008; Miyazaki et al., 2011). Besides regulating Glut4 expression, Sp1 and
Ppard have also been shown to regulated Hk2 transcription (Archer, 2011; Panasyuk et
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al., 2012). In order to uncover the mechanism by which loss of Bmal1 results in
downregulation of Glut4 and Hk2, impaired glucose uptake and decreased glycolytic
flux, it would be beneficial to assess Sp1 and Ppard in the iMSBmal1-/- mice. One might
also conduct luciferase assays in order to evaluate overexpression and knockdown of
Bmal1 in skeletal muscle cells on Sp1 and Ppard expression. If loss of Bmal1 results in
decreased Sp1 and Ppard expression it could partially explain the reduced Glut4 and Hk2
and begin to get at a mechanism.
Another substantial question emerging from this dissertation is the question of
how insulin tolerance appears to be improved in the iMSBmal1-/- mice. As mentioned
previously, other tissues metabolic tissues may be compensating. The gold standard for
evaluating physiological responses to insulin is clamp studies. To further examine insulin
action on blood glucose and obtain data on glucose disposal and output, clamp studies
would be required. To go even deeper into uptake by different tissues a study could be
done using clamp studies and radiolabeled glucose (Chen et al., 2006; Tam et al., 2012).
With this, it would be possible to determine the contribution of the different tissues to
glucose clearance. The iMSBmal1-/- mice not only exhibited a greater drop in blood
glucose in response to insulin, but they took longer to return to normal. This implies a
defect in counterregulatory mechanisms. As previously mentioned, counterregulatory
mechanisms involve release of hormones (glucagon, epinephrine, norepinephrine, growth
hormone and cortisol, increased gluconeogenesis and increased glycogenolysis (Sprague
and Arbelaez, 2011). Therefore, it would be informative to collect blood during an insulin
tolerance test and test for levels of counterregulatory hormones. In addition, one might
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look at major gluconeogenic and glycogenolytic proteins in the liver, which is
responsible for the majority of endogenous glucose production (Kishore et al., 2006).
The current dissertation only went out to 12 weeks post-recombination in the
iMSBmal1-/- mice. For the most part experiments were done only at the 5 week postrecombination timepoint. Another possible study would be to follow these metabolic
phenotype of these mice to later timepoints. The body composition may change even
more and the impairments in glucose uptake and glycolytic flux may become even more
severe. Our mice exhibited significantly elevated plasma insulin at 5 weeks postrecombination but perhaps they will lose insulin secretion all together with aging. This
would be similar to what is observed in type II diabetes. Initially insulin secretion is
higher to compensate for the insulin resistance, but this causes inflammation and damage
to the pancreatic beta cells eventually resulting in loss impaired insulin secretion (Marieb
and Hoehn, 2012).
A very intriguing experiment would be experiments involving changes in diet.
The iMSBmal1-/- mice appear to have decreased glucose oxidation. It would be very
interesting to put these mice on mostly-carbohydrate (low-fat), or all-carbohydrate diets
and observe the effects. Metabolic cage experiments could be done to obtain data such as
activity, feeding, RER and VO2. Exercise experiments (run-to-exhaustion) could be done
on normal and altered diets to see how iMSBmal1-/- mice perform. Overall health could
be observed over time. Since the iMSBmal1-/- mice don’t oxidize glucose well, it would
be expected that mice would not perform well on an all carbohydrate diet and may get
sick and show symptoms much more quickly.
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Finally, it would be interesting to do experiments in which Bmal1was rescued in
the iMSBmal1-/- mice to see if the skeletal muscle glucose uptake and glycolysis could be
improved. Perhaps one could damage the muscle on one side of the body using BaCl in
order to stimulate satellite cell fusion in that muscle. As mentioned earlier, satellite cell
Bmal1 is not knocked down in our model, so if they fuse into the muscle they add in
Bmal1 (Fry et al., 2014). Another method would be to transfect Bmal1in vivo back into
the muscle (Wan et al., 2012). Then experiments on the skeletal muscle (glucose uptake,
glycogen assays, metabolomics) could be repeated to evaluate if any improvement
occurred.

4.3 Future Goals/Plans
My immediate plans after graduation involve applying for scientific policymaking
fellowships (AAAS, presidential management, etc.). Most of the fellowship applications
are due this fall, finalize decisions in next spring and begin next fall. My primary goal is
to get one of these fellowships so that I could learn and gain experience in the 2016-17
year and try to work somewhere such as NIH, NSF or the FDA in establishing policy or
as a grants officer. I also have a strong interest in teaching, in particular at a liberal arts
type college/university. I started teaching at Bluegrass Community and Technical College
this last summer and and going to continue teaching there. I am also getting applications
together for Eastern Kentucky University, Asbury University and Transylvania
University for adjunct faculty positions. I want to gain as much teaching experience as
possible while I wait to hear about the scientific policymaking fellowships. This will
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allow me to build my CV while I wait and then if I am not fortunate enough to get a
fellowship I have instructing experience and will pursue a full-time job teaching. I have
been lucky enough to have science professors along the way that have made learning
exciting for me and inspired me. Hopefully I will be able to do that for students I may
have in the future.
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APPENDIX:

Plasma triglycerides in the iMSBmal1+/+ and iMSBmal1-/- mice. Blood was collected 5
weeks post-recombination, 2 hours after the lights went off (n=7/group; 2 mice in each
group were female).

Glucose tolerance at ZT2 ( n=7 iMSBmal1+/+ and 10 iMSBmal1-/-; 3 tamoxifen mice were
female) and ZT14 (n=8/group; 2 mice in each group were female) in the iMSBmal1+/+
and iMSBmal1-/- mice. To differentiate between genotype, black lines were used for
iMSBmal1+/+ mice and gray lines were used for iMSBmal1-/- mice. To differentiate
between time of test, dotted lines were used for ZT2 while soid lines were used for
ZT14.
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Plasma insulin during a glucose tolerance test in the iMSBmal1+/+ and iMSBmal1-/- mice.
Baseline insulin was measured and then mice were injected (IP) with a bolus of glucose
(2g/kg body weight). Blood was collected at 15, 30 and 60 minutes post glucose injection
(n=7/group; 2 female mice per group).
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